These findings introduce innovative strategies that aim to circumvent the ineffectiveness of metformin in glycemic control among T2D patients: (1) reduction of the overproduction of TGF-β1 and (2) suppression of the TGF-β1 signaling pathway. This evidence concerns the gene TGFB1 and type 2 diabetes mellitus.